tiprankstipranks
Certara, Inc. (DE:700)
NASDAQ:700
Germany Market

Certara (700) Stock Forecast & Price Target

5 Followers
See the Price Targets and Ratings of:

700 Analyst Ratings

Moderate Buy
9Ratings
Moderate Buy
3 Buy
6 Hold
0 Sell
Based on 9 analysts giving stock ratings to
Certara
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

700 Stock 12 Month Forecast

Average Price Target

€6.77
▲(31.71% Upside)
Based on 9 Wall Street analysts offering 12 month price targets for Certara in the last 3 months. The average price target is €6.77 with a high forecast of €8.67 and a low forecast of €5.20. The average price target represents a 31.71% change from the last price of €5.14.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"€3","12":"€12","5.25":"€5.25","7.5":"€7.5","9.75":"€9.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":8.665699,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€8.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6.7700773437500015,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€6.77</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5.1994194,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€5.20</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,5.25,7.5,9.75,12],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.07,5.346592230769231,5.623184461538462,5.899776692307692,6.176368923076923,6.452961153846154,6.729553384615384,7.006145615384615,7.282737846153847,7.559330076923077,7.835922307692307,8.11251453846154,8.389106769230768,{"y":8.665699,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.07,5.200775180288462,5.331550360576924,5.462325540865385,5.593100721153847,5.723875901442309,5.85465108173077,5.985426262019232,6.116201442307693,6.246976622596155,6.3777518028846165,6.508526983173079,6.63930216346154,{"y":6.7700773437500015,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.07,5.079955338461539,5.089910676923077,5.099866015384616,5.109821353846154,5.119776692307693,5.129732030769231,5.139687369230769,5.1496427076923075,5.159598046153846,5.1695533846153845,5.179508723076923,5.1894640615384615,{"y":5.1994194,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":9.578,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.822,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.244,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.264,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.41,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.04,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.79,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.546,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.264,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.154,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.724,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.084,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.07,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€8.67Average Price Target€6.77Lowest Price Target€5.20
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Robert W. Baird Analyst forecast on DE:700
Robert W. Baird
Robert W. Baird
€6.07€5.2
Hold
1.16%
Upside
Reiterated
05/12/26
Certara price target lowered to $6 from $7 at BairdCertara price target lowered to $6 from $7 at Baird
Morgan Stanley Analyst forecast on DE:700
Morgan Stanley
Morgan Stanley
€9.53€8.67
Hold
68.59%
Upside
Reiterated
05/12/26
Certara price target lowered to $10 from $11 at Morgan StanleyCertara price target lowered to $10 from $11 at Morgan Stanley
Barclays Analyst forecast on DE:700
Barclays
Barclays
€6.93€5.63
Hold
9.59%
Upside
Assigned
05/12/26
Certara price target lowered to $6.50 from $8 at BarclaysCertara price target lowered to $6.50 from $8 at Barclays
William Blair Analyst forecast on DE:700
William Blair
William Blair
Hold
Reiterated
05/12/26
Analysts' Top Healthcare Picks: Certara (CERT), Gilead Sciences (GILD)
Craig-Hallum Analyst forecast on DE:700
Craig-Hallum
Craig-Hallum
€8.67€6.93
Hold
34.87%
Upside
Reiterated
05/12/26
Analysts' Top Healthcare Picks: Neurocrine (NBIX), Certara (CERT)
BMO Capital Analyst forecast on DE:700
BMO Capital
BMO Capital
€6.07€5.2
Hold
1.16%
Upside
Reiterated
05/12/26
Certara price target lowered to $6 from $7 at BMO CapitalCertara price target lowered to $6 from $7 at BMO Capital
Stephens
€8.67€7.8
Buy
51.73%
Upside
Reiterated
05/12/26
Certara price target lowered to $9 from $10 at StephensCertara price target lowered to $9 from $10 at Stephens
TD Cowen
€8.67€7.8
Buy
51.73%
Upside
Assigned
05/11/26
Analysts Offer Insights on Healthcare Companies: Certara (NASDAQ: CERT) and Dyne Therapeutics (NASDAQ: DYN)
KeyBanc
€8.67€6.93
Buy
34.87%
Upside
Assigned
04/13/26
Analysts Offer Insights on Healthcare Companies: IDEAYA Biosciences (NASDAQ: IDYA) and Certara (NASDAQ: CERT)
RBC Capital Analyst forecast on DE:700
RBC Capital
RBC Capital
€13€8.67
Buy
68.59%
Upside
Assigned
03/09/26
Certara: Capitalizing on Growing Biosimulation Adoption Despite Near-Term Software Headwinds
Leerink Partners Analyst forecast on DE:700
Leerink Partners
Leerink Partners
€11.27
Buy
119.17%
Upside
Upgraded
01/06/26
Certara upgraded to Outperform from Market Perform at LeerinkCertara upgraded to Outperform from Market Perform at Leerink
Rothschild & Co Redburn Analyst forecast on DE:700
Rothschild & Co Redburn
Rothschild & Co Redburn
€8.67
Buy
68.59%
Upside
Initiated
11/21/25
Certara initiated with a Buy at Rothschild & Co RedburnCertara initiated with a Buy at Rothschild & Co Redburn
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Robert W. Baird Analyst forecast on DE:700
Robert W. Baird
Robert W. Baird
€6.07€5.2
Hold
1.16%
Upside
Reiterated
05/12/26
Certara price target lowered to $6 from $7 at BairdCertara price target lowered to $6 from $7 at Baird
Morgan Stanley Analyst forecast on DE:700
Morgan Stanley
Morgan Stanley
€9.53€8.67
Hold
68.59%
Upside
Reiterated
05/12/26
Certara price target lowered to $10 from $11 at Morgan StanleyCertara price target lowered to $10 from $11 at Morgan Stanley
Barclays Analyst forecast on DE:700
Barclays
Barclays
€6.93€5.63
Hold
9.59%
Upside
Assigned
05/12/26
Certara price target lowered to $6.50 from $8 at BarclaysCertara price target lowered to $6.50 from $8 at Barclays
William Blair Analyst forecast on DE:700
William Blair
William Blair
Hold
Reiterated
05/12/26
Analysts' Top Healthcare Picks: Certara (CERT), Gilead Sciences (GILD)
Craig-Hallum Analyst forecast on DE:700
Craig-Hallum
Craig-Hallum
€8.67€6.93
Hold
34.87%
Upside
Reiterated
05/12/26
Analysts' Top Healthcare Picks: Neurocrine (NBIX), Certara (CERT)
BMO Capital Analyst forecast on DE:700
BMO Capital
BMO Capital
€6.07€5.2
Hold
1.16%
Upside
Reiterated
05/12/26
Certara price target lowered to $6 from $7 at BMO CapitalCertara price target lowered to $6 from $7 at BMO Capital
Stephens
€8.67€7.8
Buy
51.73%
Upside
Reiterated
05/12/26
Certara price target lowered to $9 from $10 at StephensCertara price target lowered to $9 from $10 at Stephens
TD Cowen
€8.67€7.8
Buy
51.73%
Upside
Assigned
05/11/26
Analysts Offer Insights on Healthcare Companies: Certara (NASDAQ: CERT) and Dyne Therapeutics (NASDAQ: DYN)
KeyBanc
€8.67€6.93
Buy
34.87%
Upside
Assigned
04/13/26
Analysts Offer Insights on Healthcare Companies: IDEAYA Biosciences (NASDAQ: IDYA) and Certara (NASDAQ: CERT)
RBC Capital Analyst forecast on DE:700
RBC Capital
RBC Capital
€13€8.67
Buy
68.59%
Upside
Assigned
03/09/26
Certara: Capitalizing on Growing Biosimulation Adoption Despite Near-Term Software Headwinds
Leerink Partners Analyst forecast on DE:700
Leerink Partners
Leerink Partners
€11.27
Buy
119.17%
Upside
Upgraded
01/06/26
Certara upgraded to Outperform from Market Perform at LeerinkCertara upgraded to Outperform from Market Perform at Leerink
Rothschild & Co Redburn Analyst forecast on DE:700
Rothschild & Co Redburn
Rothschild & Co Redburn
€8.67
Buy
68.59%
Upside
Initiated
11/21/25
Certara initiated with a Buy at Rothschild & Co RedburnCertara initiated with a Buy at Rothschild & Co Redburn
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Certara

3 Months
Dan LeonardRBC Capital
Success Rate
4/6 ratings generated profit
67%
Average Return
-2.55%
Copying Dan Leonard's trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of -2.55% per trade.
1 Year
Success Rate
1/5 ratings generated profit
20%
Average Return
-19.20%
Copying Jeffrey Garro's trades and holding each position for 1 Year would result in 20.00% of your transactions generating a profit, with an average return of -19.20% per trade.
2 Years
Success Rate
1/5 ratings generated profit
20%
Average Return
-33.84%
Copying Jeffrey Garro's trades and holding each position for 2 Years would result in 20.00% of your transactions generating a profit, with an average return of -33.84% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

700 Analyst Recommendation Trends

Rating
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Strong Buy
0
0
0
2
2
Buy
13
9
6
2
1
Hold
6
5
10
15
14
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
19
14
16
19
17
In the current month, 700 has received 3 Buy Ratings, 14 Hold Ratings, and 0 Sell Ratings. 700 average Analyst price target in the past 3 months is 6.77.
Each month's total comprises the sum of three months' worth of ratings.

700 Financial Forecast

700 Earnings Forecast

Next quarter’s earnings estimate for 700 is €0.08 with a range of €0.07 to €0.09. The previous quarter’s EPS was €0.08. 700 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year 700 has Performed in-line its overall industry.
Next quarter’s earnings estimate for 700 is €0.08 with a range of €0.07 to €0.09. The previous quarter’s EPS was €0.08. 700 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year 700 has Performed in-line its overall industry.

700 Sales Forecast

Next quarter’s sales forecast for 700 is €83.96M with a range of €81.26M to €86.46M. The previous quarter’s sales results were €91.07M. 700 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year 700 has Performed in-line its overall industry.
Next quarter’s sales forecast for 700 is €83.96M with a range of €81.26M to €86.46M. The previous quarter’s sales results were €91.07M. 700 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year 700 has Performed in-line its overall industry.

700 Stock Forecast FAQ

What is DE:700’s average 12-month price target, according to analysts?
Based on analyst ratings, Certara, Inc.’s 12-month average price target is 6.77.
    What is DE:700’s upside potential, based on the analysts’ average price target?
    Certara, Inc. has 31.71% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Certara, Inc. a Buy, Sell or Hold?
          Certara, Inc. has a consensus rating of Moderate Buy, which is based on 3 buy ratings, 6 hold ratings and 0 sell ratings.
            What is Certara, Inc.’s share price target?
            The average share price target for Certara, Inc. is 6.77. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €8.67 ,and the lowest forecast is €5.20. The average share price target represents 31.71% Increase from the current price of €5.14.
              What do analysts say about Certara, Inc.?
              Certara, Inc.’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 9 Wall Streets Analysts.
                How can I buy shares of Certara, Inc.?
                To buy shares of DE:700, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.